Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

salbutamol/ albuterol

PreclinicalSmall molecule

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

TachypneaActive, not recruiting

TachypneaPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

N/ANot yet recruiting

Tachypnea

NCT07350421

Clinical

Trials by Indication[1]

Asthma2 trials

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

Completed·MMannkind Corporation·Phase 1·NCT00673621·30 enrolled

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

Withdrawn· Novartis logo

Novartis·Phase 3·NCT02127697

Tachypnea1 trial

The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN)

Not yet recruiting·TTishreen University·N/A·NCT07350421·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for salbutamol/ albuterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — salbutamol/ albuterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for salbutamol/ albuterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

Related News